These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24378092)

  • 1. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
    Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bufalin reverses hepatocyte growth factor-induced resistance to afatinib in H1975 lung cancer cells].
    Kang X; Lu P; Cui Y; Wang Y; Zhang Q; Gong Y; Xu Z
    Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):490-6. PubMed ID: 26463323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
    Coco S; Truini A; Alama A; Dal Bello MG; Venè R; Garuti A; Carminati E; Rijavec E; Genova C; Barletta G; Sini C; Ballestrero A; Boccardo F; Grossi F
    Target Oncol; 2015 Sep; 10(3):393-404. PubMed ID: 25341405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
    Zhou Y; Zhang S; Li K; Li QW; Zhou FZ; Li ZY; Ma H; Dong XR; Liu L; Wu G; Meng R
    Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):100-4. PubMed ID: 26899328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
    Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
    Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
    Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of bufalin combined gefitinib on lung cancer H1975 cells and its mechanisms research].
    Kang XH; Gong YB; Wang LF; Wang ZQ; Deng HB; Zhao XZ; Wu J; Xu ZY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Aug; 33(8):1081-5. PubMed ID: 24325059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
    Xu J; Liu S; Yang X; Cao S; Zhou Y
    Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway.
    Shen Y; Chen Q; Li L
    Mol Cell Probes; 2019 Jun; 45():57-64. PubMed ID: 31096000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
    Uramoto H; Shimokawa H; Hanagiri T; Kuwano M; Ono M
    Lung Cancer; 2011 Sep; 73(3):361-5. PubMed ID: 21315472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.